Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-Acetyl γ calicheamicin dimethyl hydrazide targets lewis y and eliminates lewisy-positive human carcinoma cells and xenografts

Clinical Cancer Research

Volumn 10, Issue 13, 2004, Pages 4538-4549

  Boghaert, Erwin R ^a   Sridharan, Latha ^a   Armellino, Douglas C ^a   Khandke, Kiran M ^a   DiJoseph, John F ^a   Kunz, Arthur ^a   Dougher, Maureen M ^a   Jiang, Fan ^a   Kalyandrug, Lyka B ^a   Hamann, Philip R ^a   Frost, Philip ^a   Damle, Nitin K ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALICHEAMICIN DERIVATIVE; CYTOTOXIC AGENT; HU3S193; N ACETYL GAMMA CALICHEAMICIN DIMETHYL HYDRAZIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; BLOOD GROUP LEWIS SYSTEM; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; XENOGRAFT;

AMINOGLYCOSIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS; CARCINOMA; CELL LINE, TUMOR; CELL SEPARATION; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG COMBINATIONS; ENEDIYNES; FEMALE; FLOW CYTOMETRY; HUMANS; HYDRAZINES; HYDROLYSIS; IMMUNOTHERAPY; KINETICS; LAMININ; LEWIS BLOOD-GROUP SYSTEM; MALE; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; PROTEOGLYCANS; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE; TISSUE DISTRIBUTION;

EID: 3042770596     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0037     Document Type: Article

References (38)

1. Kalwinsky DK. Therapy for acute leukemias in children. Curr Opin Oncol 1991;3:39-43.
2. Dusenbery KE, Peterson BA, Bloomfield CD. Chemotherapy with cyclophosphamide, vinblastin, procarbazine and prednisone (CVPP) for Hodgkin disease: fourteen-year follow-up results. Am J Hematol 1988; 28:246-51.
3. Gottesman MM. Mechanisms of cancer drug resistance. Ann Rev Med 2002;53:615-27.
4. Mashima T, Tsuruo T. Apoptosis as a novel target for for cancer chemotherapy. Biotherapy 1998;12:947-52.
5. Mareel MM, Bracke ME, Boghaert ER. Tumor invasion and metastasis, major causes of therapeutic failure. Radiother Oncol 1986;6: 135-42.
6. Ehrlich P. Collected studies on immunity (reprinted). 1906. New York: Wiley. p. 404-442.
7. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-84.
8. Kreitman RJ. Recombinant toxins for the treatment of cancer. Curr Opin Mol Ther 2003;5:44-51.
9. Zelenetz AD. A clinical and scientific overview of tositumomab and iodine I131 tositumomab. Semin Oncol 2003;30(2 Suppl 4):22-30.
10. Forero A, Lobuglio AF. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 2003;30(6 Suppl 17):1-5.
11. Hamann PR, Hinman LM, Hollander I, et al. A potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13:47-58.
12. 1: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240:1198-201.
13. Nielsen UB, Kirpotin DB, Pickering EM, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta-Mol Cell Res 2002; 1591(1-3):109-18.
14. Shinohara H, Morita S, Kawai M, et al. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide stabilized anti-HER2 immunotoxin. J Surg Res 2002;102:169-77.
15. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: Tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
16. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large tumor xenografts by targeted delivery of maytansinoids. Proc Nat Acad Sci USA 1996;93:8618-23.
17. Suwa T, Ueda M, Jinno H, et al. Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody ribonuclease conjugate on human cancer cells. Anticancer Res 1999;19:4161-5.
18. Starling JJ, Maciak RS, Hinson NA, et al. In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigen. Bioconj Chem 1992;3:315-22.
19. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment B lymphoid malignancies. Blood 2004; 103:1807-14.
20. Sjogren HO, Isaksson M, Willner D, Hellstrom I, Hellstrom KE, Trail PA. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic nude mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 1997; 57:4530-6.
21. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Ley-related cell surface antigens. Cancer Res 1990;50:2183-90.
22. Scott AM, Geleick D, Rubira M, et al. Construction, production and characterization of humanized anti-LewisY monoclonal antibody 3S 193 for targeted immunotherapy of solid tumors. Cancer Res 2000;60: 3254-61.
23. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group related antigens. Int J Cancer 1997;73:50-6.
24. Wahl AF, Donalson KL, Mixan BJ, Trail PA, Siegall CB. Selective tumor sensitization to taxanes with the Mab-drug conjugate cBR96-doxorubicin. Int J Cancer 2000;93:590-600.
25. Furukawa K, Welt S, Yin BW, et al. Analysis of fine specificities of eleven mouse monoclonal antibodies reactive with type 2 blood group determinants. Mol Immunol 1990;27:723-32.
26. y determinants. Proc Natl Acad Sci USA 1994;91:12957-61.
27. Clarke K, Lee F-T, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice Cancer Res 2000;60:4804-11.
28. Vermeulen SJ, Bruyneel EA, Bracke ME, et al. Transition from the noninvasive to the invasive phenotype and loss of alpha- catenin in human colon cancer cells. Cancer Res 1995;55:4722-8.
29. Attia MA, Weiss DW. Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain-A mice infected with mammary tumor virus Cancer Res 1966; 26:1787-800.
30. Garrigues J, Garrigues U, Hellstrom I, Hellstrom KE. LeY specific antibody with potent anti-tumor activity is internalized and degraded in lysosomes. Am J Pathol 1993;142:607-22.
31. Takakura Y, Fujita T, Hashida M, Sezaki H. Disposition characteristics of macromolecules in tumor-bearing mice. Pharm Res 1990;7: 339-46.
32. Matsumura Y, Maeda HA. A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986;6:6387-92.
33. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 1990;9:253-66.
34. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3:1031-44.
35. Jedema I, Barge RMY, van der Velden VHJ, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia 2004,18:316-25.
36. Trail PA, Willner D, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261:212-5.
37. Tolcher AW, Sugarman S, Gelman KA, et al. Randomized phase II study on BR96-doxorubicin conjugate in patients with metastatic breast cancer. Journal of Clinical Oncology 1999;17:478-5.
38. Hoffman EW, Scott AM, Divgi CR, et al. Phase I trials of CDR-grafted humanized monoclonal antibody hu3S193 in patients with Lewis-Y expressing solid tumors. Proceedings of the 37th Annual Meeting of the American Society for Clinical Oncology, 2001, San Francisco, Alexandria, VA: ASCO, 2001.